$1.04 Billion is the total value of Consonance Capital Management LP's 23 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was 86.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CLVS | Buy | CLOVIS ONCOLOGY INC | $127,310,000 | +216.0% | 3,531,487 | +20.3% | 12.25% | +114.9% |
| ARIA | Sell | ARIAD PHARMACEUTICALS INC | $119,045,000 | +82.1% | 8,695,742 | -1.7% | 11.46% | +23.8% |
| MNKKQ | MALLINCKRODT PUB LTD CO | $108,837,000 | +14.8% | 1,560,157 | 0.0% | 10.48% | -21.9% | |
| UTHR | Buy | UNITED THERAPEUTICS CORP DEL | $96,672,000 | +118.0% | 818,700 | +95.5% | 9.30% | +48.2% |
| AMRN | New | AMARIN CORP PLCspons adr new | $78,641,000 | – | 24,652,380 | +100.0% | 7.57% | – |
| RTRX | Buy | RETROPHIN INC | $69,041,000 | +43.6% | 3,084,947 | +14.3% | 6.64% | -2.4% |
| HZNP | New | HORIZON PHARMA PLC | $67,061,000 | – | 3,698,903 | +100.0% | 6.46% | – |
| AKRXQ | New | AKORN INC | $59,972,000 | – | 2,200,000 | +100.0% | 5.77% | – |
| IRWD | Sell | IRONWOOD PHARMACEUTICALS INC | $52,349,000 | -18.8% | 3,296,539 | -33.1% | 5.04% | -44.8% |
| MD | New | MEDNAX INC | $43,725,000 | – | 660,000 | +100.0% | 4.21% | – |
| ANIP | Sell | ANI PHARMACEUTICALS INC | $43,344,000 | -5.0% | 653,258 | -20.1% | 4.17% | -35.4% |
| GMED | New | GLOBUS MED INCcl a | $41,980,000 | – | 1,860,000 | +100.0% | 4.04% | – |
| MACK | New | MERRIMACK PHARMACEUTICALS IN | $37,784,000 | – | 5,950,225 | +100.0% | 3.64% | – |
| OFIX | Sell | ORTHOFIX INTL N V | $27,137,000 | -47.7% | 634,496 | -48.2% | 2.61% | -64.5% |
| MYGN | New | MYRIAD GENETICS INC | $17,485,000 | – | 850,000 | +100.0% | 1.68% | – |
| EHTH | New | EHEALTH INC | $12,944,000 | – | 1,154,711 | +100.0% | 1.25% | – |
| HSTM | New | HEALTHSTREAM INC | $9,407,000 | – | 340,847 | +100.0% | 0.90% | – |
| ADMA | ADMA BIOLOGICS INC | $9,223,000 | +21.7% | 1,273,933 | 0.0% | 0.89% | -17.2% | |
| VCEL | VERICEL CORP | $6,252,000 | +24.4% | 2,232,940 | 0.0% | 0.60% | -15.3% | |
| ATRC | New | ATRICURE INC | $3,667,000 | – | 231,926 | +100.0% | 0.35% | – |
| BIOL | Buy | BIOLASE INC | $3,134,000 | +113.1% | 1,790,992 | +42.4% | 0.30% | +45.2% |
| SPNE | Buy | SEASPINE HLDGS CORP | $2,658,000 | -0.7% | 262,934 | +3.0% | 0.26% | -32.5% |
| VCYT | VERACYTE INC | $1,262,000 | +51.3% | 165,825 | 0.0% | 0.12% | +2.5% | |
| AXGN | Exit | AXOGEN INC | $0 | – | -526,351 | -100.0% | -0.51% | – |
| PACB | Exit | PACIFIC BIOSCIENCES CALIF IN | $0 | – | -1,114,448 | -100.0% | -1.11% | – |
| NUVA | Exit | NUVASIVE INC | $0 | – | -165,203 | -100.0% | -1.40% | – |
| CPHD | Exit | CEPHEID | $0 | – | -453,662 | -100.0% | -1.97% | – |
| NXTM | Exit | NXSTAGE MEDICAL INC | $0 | – | -835,134 | -100.0% | -2.56% | – |
| EGRX | Exit | EAGLE PHARMACEUTICALS INC | $0 | – | -482,047 | -100.0% | -2.65% | – |
| PEN | Exit | PENUMBRA INC | $0 | – | -684,079 | -100.0% | -5.76% | – |
| DEPO | Exit | DEPOMED INC | $0 | – | -2,275,300 | -100.0% | -6.32% | – |
| MDVN | Exit | MEDIVATION INC | $0 | – | -1,270,000 | -100.0% | -10.84% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITED THERAPEUTICS CORP DEL | 29 | Q2 2022 | 15.9% |
| ADMA BIOLOGICS INC | 27 | Q4 2020 | 2.3% |
| RETROPHIN INC | 23 | Q1 2020 | 11.3% |
| ANI PHARMACEUTICALS INC | 23 | Q3 2019 | 7.9% |
| VERICEL CORP | 21 | Q4 2019 | 5.5% |
| AMARIN CORP PLC | 14 | Q3 2019 | 14.4% |
| GLOBUS MED INC | 13 | Q2 2022 | 24.7% |
| ORTHOFIX INTL N V | 13 | Q3 2016 | 9.7% |
| PACIFIC BIOSCIENCES CALIF IN | 13 | Q4 2018 | 9.7% |
| CATALYST PHARM PARTNERS INC | 13 | Q3 2019 | 9.4% |
View Consonance Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Surrozen, Inc./DESold out | December 15, 2022 | 0 | 0.0% |
| ADMA BIOLOGICS, INC. | February 14, 2022 | 1,289,481 | 1.4% |
| ASSEMBLY BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| CASI Pharmaceuticals, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Cellectar Biosciences, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Gamida Cell Ltd.Sold out | February 14, 2022 | 0 | 0.0% |
| GenMark Diagnostics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Protagonist Therapeutics, IncSold out | February 14, 2022 | 0 | 0.0% |
| Sio Gene Therapies Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Consonance-HFW Acquisition Corp. | April 27, 2021 | 1,000,000 | 10.4% |
View Consonance Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2022-12-15 |
| SC 13D/A | 2022-12-15 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Consonance Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.